ANVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ANVS ▲ +8.25% at T+5d

SHORT call ✗ call lost -8.25% · α vs SPY -7.29% · entry $2.06 → $2.23

Next anchor: T+20d in 4h

Last close $1.78 (close Jun 12) · +13.59% from $2.06 entry (call sign-flipped)

Entry anchored
May 15, 2026
via day open

T+1d

-0.49%

call +0.49% · α +0.42%

$2.05

settled 28d ago

T+5d

+8.25%

call -8.25% · α -7.29%

$2.23

settled 24d ago

T+20d

—

call — · α —

—

in 4h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses tripling to $16.7M as the Phase 3 AD trial enrollment reached 85%. Cash burn accelerated to $17.6M net loss for the quarter, leaving $14.2M cash on hand (plus $10M from an April offering), funding operations into late 2026 but raising dilution risk ahead of pivotal data readouts in early 2027.

Actionable Insight

The EPS miss and accelerating cash burn are negative signals for a pre-revenue biotech with no near-term catalyst until summer 2026 enrollment completion. Monitor cash runway closely — the $14.2M cash (plus $10M offering) likely funds operations only into late 2026, requiring additional financing before Phase 3 data readout in early 2027. The 85% enrollment milestone is positive but insufficient to offset the financial deterioration.

Key Facts

Q1 2026 EPS -$0.63 vs consensus -$0.35 (80% miss); net loss widened to $17.6M from $5.5M YoY
Cash and equivalents $14.2M at March 31, 2026, down from $19.5M at year-end 2025; excludes $10M April offering
Phase 3 AD trial 85% enrolled; full enrollment expected summer 2026, top-line symptomatic data early 2027
R&D expenses $16.7M vs $5.0M YoY, driven by Phase 3 trial costs; G&A flat at $1.3M
Shares outstanding 28.5M at March 31, up from 27.2M at year-end 2025, reflecting ongoing dilution

Financial Impact

EPS miss of -$0.28 vs consensus; net loss increased $12.1M YoY; cash burn rate ~$5.9M/month

epscashnet lossdilution

Risk Factors

Cash runway insufficient to reach Phase 3 data readout without dilutive financing
EPS miss and widening losses may pressure the stock given limited analyst coverage (1 analyst)
Regulatory and clinical execution risk for buntanetap NDA submission in early 2027

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295755

7 reports for ANVS

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ANVS — sortable, filterable
	Type				Now
May 20, 2026 25d ago	424B5 BEARISH ★ 6/10	$2.15 $1.90	▲ +11.63%	▲ +13.23%	$1.78 (+17.21%)
May 19, 2026 26d ago	424B5 BEARISH ★ 7/10	$2.04 $2.01	▲ +1.47%	▲ +2.71%	$1.78 (+12.75%)
May 15, 2026 4w ago	8-K MIXED ★ 5/10	$2.05 $2.06	▲ +0.49%	▼ −1.13%	$1.78 (−13.17%)
May 15, 2026 4w ago	Press Release BEARISH ★ 6/10	$2.06 $2.23	▼ −8.25%	▼ −7.29%	$1.78 (+13.59%)
Apr 10, 2026 9w ago	Press Release MIXED ★ 6/10	$1.59 $1.87	▲ +17.61%	▲ +13.11%	$1.78 (+11.95%)
Mar 19, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.15	▼ −19.48%	▼ −17.26%	$1.78 (−33.33%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.83 $2.50	▼ −11.66%	▼ −9.62%	$1.78 (−37.10%)

US Market Status

Market Closed — Opens in 5h 8m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access